Clinical Trial Update: A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating anlotinib combined with penpulimab in gynecological cancer is in early results with unknown current status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gynecological Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Penpulimab

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: Gynecological Cancer | Phase 2 | Status: UNKNOWN